Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Prostatic Neoplasms 16Carcinoma, Renal Cell 14Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Neoplasms 6Carcinoma, Medullary 6Thyroid Neoplasms 5Melanoma 5Breast Neoplasms 5Ovarian Neoplasms 4Neuroendocrine Tumors 4Carcinoma, Transitional Cell 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Kidney Neoplasms 3Adenocarcinoma, Follicular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Pain 2Osteosarcoma 2Multiple Myeloma 2

Interventions

Octreotide 5Everolimus 4pasireotide 3lanreotide 3ganitumab 2gallium Ga 68 dotatate 2cabozantinib 2Nivolumab 2Erlotinib Hydrochloride 2surufatinib 1pertuzumab 1nintedanib 1ibrutinib 1fosbretabulin 1conatumumab 1cixutumumab 1carfilzomib 1arginyllysine 1aflibercept 1Temozolomide 1Sunitinib 1Somatostatin 1Random Allocation 1Ramucirumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Capecitabine 1Bevacizumab 1Axitinib 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoid Tumor × cabozantinib × Clear all
NCT04197310 2025-01-31

Cabozantinib and Nivolumab for Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
19 enrolled 10 charts
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT01466036 2024-03-05

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
61 enrolled 9 charts
Endocrine

Carcinoid Tumor, Adenoma, Islet Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡